Two nonionic MRI contrast agents, Prohance and Omniscan, are inchingcloser to Food and Drug Administration approval. But despite afavorable review by the agency's medical imaging drugs advisorycommittee meeting last month, the agents are still nearly a
Two nonionic MRI contrast agents, Prohance and Omniscan, are inchingcloser to Food and Drug Administration approval. But despite afavorable review by the agency's medical imaging drugs advisorycommittee meeting last month, the agents are still nearly a yearaway from the open market.
"No formal vote was taken, due to lack of a quorum, butin both instances the committee was favorably disposed to thesetwo agents," said Leander B. Madoo, executive secretary forthe imaging drugs advisory committee.
The committee considered new drug application (NDA) data evaluatedby Dr. Hsien Ju, a medical officer in the FDA's division of medicalimaging. The data included results from phase three clinical trialsconducted by Squibb Diagnostics (Bristol-Myers Squibb) for Prohanceand by Sterling Drug (Sterling Winthrop) for Omniscan. Ju spentonly 20 minutes discussing each agent.
"That short amount of time for review is indicative thatthere weren't many questions about the agents," Madoo said.
Committee members did raise concerns about the lack of dosecalibration data in the studies, however, and noted that a phasefour study may be required either prior to or post-FDA approval.
A firm time line for approval was one of several details theadvisory committee discussed in closed session. Without elaboratingon that discussion, Madoo said the agency is interested in expeditingapproval, which could occur within a year.
"Just because things look good from a clinical standpointdoesn't mean that a few kinks don't need to be worked out, interms of labeling and production," he said.
Representatives from Sterling and Squibb would not commenton the committee meeting.
Only Berlex's Magnevist is currently FDA-approved for MR applications.Although not a nonionic, it is considered one of the safest agentsin both delayed as well as bolus injections.
Eventual approval of the two nonionic agents will mean competitionfor Magnevist in brain and spine studies. Clinical studies ofthese agents demonstrate that increased doses are possible withoutrisk of adverse effects.
MRI-Based AI Radiomics Model Offers 'Robust' Prediction of Perineural Invasion in Prostate Cancer
July 26th 2024A model that combines MRI-based deep learning radiomics and clinical factors demonstrated an 84.8 percent ROC AUC and a 92.6 percent precision-recall AUC for predicting perineural invasion in prostate cancer cases.
Breast MRI Study Examines Common Factors with False Negatives and False Positives
July 24th 2024The absence of ipsilateral breast hypervascularity is three times more likely to be associated with false-negative findings on breast MRI and non-mass enhancement lesions have a 4.5-fold likelihood of being linked to false-positive results, according to new research.
Can Polyenergetic Reconstruction Help Resolve Streak Artifacts in Photon Counting CT?
July 22nd 2024New research looking at photon-counting computed tomography (PCCT) demonstrated significantly reduced variation and tracheal air density attenuation with polyenergetic reconstruction in contrast to monoenergetic reconstruction on chest CT.